about
T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and PerspectivesClinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study.Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group.Insulin-Like Growth Factor Binding Protein 6 in Rheumatoid Arthritis: A Possible Novel Chemotactic Factor?Expansion of regulatory GITR+CD25 low/-CD4+ T cells in systemic lupus erythematosus patients.Rituximab in primary Sjögren's syndrome: a ten-year journey.The microbial capsular polysaccharide galactoxylomannan inhibits IL-17A production in circulating T cells from rheumatoid arthritis patients.CD4(-)CD8(-) T-cells in primary Sjögren's syndrome: association with the extent of glandular involvement.Drugs in induction and treatment of idiopathic inflammatory myopathiesInterferon gamma-inducible protein 16 in primary Sjögren's syndrome: a novel player in disease pathogenesis?Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome: Results From an International Retrospective Multicenter Study.Plant-Derived Chimeric Virus Particles for the Diagnosis of Primary Sjögren Syndrome.Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study.Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new.Unmasking the pathogenic role of IL-17 axis in primary Sjögren's syndrome: a new era for therapeutic targeting?Role of regulatory T cells in rheumatoid arthritis: facts and hypothesis.Anti-SSA/SSB-negative Sjögren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution.International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphosTargeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study.Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).The onset site of rheumatoid arthritis: the joints or the lung?Interferon gamma-inducible protein 16 (IFI16) and anti-IFI16 antibodies in primary Sjögren's syndrome: findings in serum and minor salivary glands.Circulating Interferon-Inducible Protein IFI16 Correlates With Clinical and Serological Features in Rheumatoid Arthritis.Cardiovascular disease risk burden in primary Sjögren's syndrome: results of a population-based multicentre cohort study.Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren's syndrome: results of a large multicentre study.Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study.Images in clinical medicine: Unusual bursal fluid.Primary Sjogren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients.A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sjögren's syndrome.The clinical spectrum of primary Sjögren's syndrome: beyond exocrine glands.Central Hemodynamics and Arterial Stiffness in Systemic Sclerosis.Platelets Contribute to the Accumulation of Matrix Metalloproteinase Type 2 in Synovial Fluid in Osteoarthritis.Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases.IL-17-producing double-negative T cells are expanded in the peripheral blood, infiltrate the salivary gland and are partially resistant to corticosteroid therapy in patients with Sjögren's syndrome.Aortic stiffness is increased in polymyalgia rheumatica and improves after steroid treatmentIs minor salivary gland biopsy more than a diagnostic tool in primary Sjo¨gren׳s syndrome? Association between clinical, histopathological, and molecular features: A retrospective studyOutcome of Pregnancy in Italian Patients with Primary Sjögren Syndrome
P50
Q26859226-B284E8B4-1039-43ED-AE38-713FD0EB86F1Q30238667-EFC25E8E-C657-482E-B338-C9F9A7F8B547Q30251952-C527A7A7-03FB-42E1-82DD-F1E74C433960Q33700730-783C3FAA-241A-4DBE-8501-BCF966EE5974Q34401977-E43973AC-A95C-4C3B-93C7-68BBFC830200Q34432465-A719D5A2-7E81-4A7D-B5F5-16B32A514B8EQ34544926-E99E552E-7443-4038-AA45-59B518ACCA7BQ35086094-4945A396-C13D-4144-A238-626690C8AAF5Q35281940-74EE6213-4D2A-415A-A5D8-8BBDF1BB2626Q35953713-35BFA88B-9455-449D-9475-19245FF2D635Q36195131-612F7223-D8C0-4AF0-A0A6-5E6371D3AD77Q36332891-A4F5DCD4-64DD-4416-BF75-32CEB7FC2BF8Q36903191-58761E55-2BEA-4261-9B5B-93249F60B8CAQ37991040-5F2EC41B-4E63-4B7F-BD93-411990B3E179Q38023853-B557F6FA-A677-41E7-8441-D5B42D903263Q38245657-5159E2DC-27BF-45EC-9F1D-936F211AA153Q38497370-3D39C057-A7A4-436C-85F3-E26B6F2534F1Q38544929-18F29D1E-8801-40B5-9C31-5FF7C69FA54BQ38657993-2DFBE24F-70C4-47AA-8DEC-6290EDB27122Q38664951-4323D72E-4030-47D1-902D-202000972908Q38703626-93AE5042-4DA5-4E88-97D1-0200A1551313Q39081726-4D2E4439-D9B2-405F-88C4-138CEBB02039Q39181558-8D398FC1-209B-46B9-B92C-CCF795AD5B95Q39997712-7D37E583-9EE1-4ECB-A01F-6D249968E830Q40597789-27119FB8-85B8-4042-83A1-B7525A11835CQ41590963-BC955457-B447-445E-B1E1-A9FD970BBDBCQ41721609-BC14E3FC-408B-4FCB-BF5D-7C8EB7CD40A4Q42255591-D987B067-D67F-4EA6-9BC2-E41C0442E140Q44021733-0DFF5F60-B56C-418D-81A7-57F1774A7A77Q44301752-7CCEC9EC-E58B-4635-BF35-F61157BC36A0Q45828136-BF48B8EE-94FD-4EDB-A69D-0F64B0B70586Q49968784-FCC56782-6FFA-4F01-BA46-1A4BA8D9A23FQ51380352-2A3E222C-834D-4ABC-942E-C2652766F4B4Q52751952-68DAE597-F854-44A2-973D-2DF7B6257A68Q52880103-248CDE59-7663-47FE-AEDC-EB6B5FE88D92Q54060732-E340A815-5860-423A-A913-755F99DF4382Q54658714-F1641449-DAA0-4766-9B59-D12EE75A0763Q58419179-670CA25E-9009-4BFB-BA21-E73D088BDE10Q61046015-142FA90B-C19B-4165-88B9-DED5D47CCF59Q61387495-ADD413E6-702D-4A83-AD4E-EBB1D5B7B4D6
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Elena Bartoloni
@ast
Elena Bartoloni
@en
Elena Bartoloni
@es
Elena Bartoloni
@nl
Elena Bartoloni
@sl
type
label
Elena Bartoloni
@ast
Elena Bartoloni
@en
Elena Bartoloni
@es
Elena Bartoloni
@nl
Elena Bartoloni
@sl
prefLabel
Elena Bartoloni
@ast
Elena Bartoloni
@en
Elena Bartoloni
@es
Elena Bartoloni
@nl
Elena Bartoloni
@sl
P106
P1153
35798005900
P21
P31
P496
0000-0003-4776-2136